Parkman Healthcare Partners LLC Mirum Pharmaceuticals, Inc. Transaction History

Parkman Healthcare Partners LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	BUY	$24.63 - $32.85 $65,023 - $86,724	2,640 Added 4.23%	65,050 $2.06 Million
Q2 2023 Aug 11, 2023	BUY	$23.51 - $30.09 $6,864 - $8,786	292 Added 0.47%	62,410 $1.61 Million
Q1 2023 May 12, 2023	BUY	$19.19 - $24.1 $179,695 - $225,672	9,364 Added 17.75%	62,118 $1.49 Million
Q4 2022 Feb 13, 2023	BUY	$17.59 - $23.83 $182,214 - $246,854	10,359 Added 24.43%	52,754 $1.03 Million
Q3 2022 Nov 14, 2022	BUY	$19.98 - $29.44 $207,412 - $305,616	10,381 Added 32.43%	42,395 $891,000
Q2 2022 Aug 12, 2022	BUY	$18.42 - $27.5 $30,577 - $45,650	1,660 Added 5.47%	32,014 $623,000
Q1 2022 May 13, 2022	BUY	$15.5 - $23.93 $470,487 - $726,371	30,354 New	30,354 $668,000

190

54M

177K

167K

Ticker MIRM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 36,751,700
Market Cap $1.61B
Description
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the trea...

Get notified when there are updates to the investment portfolio of Parkman Healthcare Partners LLC, based on Form 13F filings with the SEC.

Stay updated on Parkman Healthcare Partners LLC with notifications on news.